Gilead Sciences licensed a clinic‑ready MAT2A inhibitor from Suzhou‑based Genhouse Bio in a deal valued at up to $1.53 billion. The program targets synthetic lethality approaches in oncology that exploit metabolic vulnerabilities in certain tumor genotypes. Under the agreement, Gilead will drive global clinical development and commercialization while Genhouse receives upfront and milestone payments tied to development progress and sales. The asset adds a targeted small‑molecule mechanism to Gilead’s expanding oncology portfolio and complements its broader strategy to invest in precision synthetic‑lethality programs. Analysts view the deal as another example of major pharmas securing ex‑US innovation to accelerate oncology pipelines and diversify mechanisms beyond immunotherapy.